Business Description
MediciNova Inc
NAICS : 325412
SIC : 2834
ISIN : US58468P2065
Total Employee Number:
6Description
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 165.63 | |||||
Equity-to-Asset | 0.92 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -2.97 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 3.2 | |||||
3-Year EPS without NRI Growth Rate | 6.1 | |||||
3-Year FCF Growth Rate | 8.7 | |||||
3-Year Book Growth Rate | -16.1 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 326.39 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 49.8 | |||||
9-Day RSI | 48.66 | |||||
14-Day RSI | 47.52 | |||||
3-1 Month Momentum % | -2.69 | |||||
6-1 Month Momentum % | 0.46 | |||||
12-1 Month Momentum % | 14.81 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 9.09 | |||||
Quick Ratio | 9.09 | |||||
Cash Ratio | 8.83 | |||||
Days Sales Outstanding | 116.16 | |||||
Days Payable | 466.85 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.1 | |||||
Shareholder Yield % | -0.03 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 8.04 | |||||
Operating Margin % | -2163.48 | |||||
Net Margin % | -1962.98 | |||||
EBITDA Margin % | -2160.47 | |||||
FCF Margin % | -1594.3 | |||||
OCF Margin % | -1592.38 | |||||
ROE % | -26.42 | |||||
ROA % | -24.61 | |||||
ROIC % | -84.43 | |||||
3-Year ROIIC % | -479 | |||||
ROC (Joel Greenblatt) % | -5368.25 | |||||
ROCE % | -28.94 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 100.86 | |||||
PB Ratio | 1.64 | |||||
Price-to-Tangible-Book | 2.57 | |||||
EV-to-EBIT | -2.87 | |||||
EV-to-Forward-EBIT | -2.5 | |||||
EV-to-EBITDA | -2.87 | |||||
EV-to-Forward-EBITDA | -2.5 | |||||
EV-to-Revenue | 62.09 | |||||
EV-to-Forward-Revenue | 198.23 | |||||
EV-to-FCF | -3.9 | |||||
| Price-to-Net-Current-Asset-Value | 2.62 | |||||
| Price-to-Net-Cash | 2.68 | |||||
Earnings Yield (Greenblatt) % | -34.84 | |||||
FCF Yield % | -14.8 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
MediciNova Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil 円) | 91.065 | ||
| EPS (TTM) (円) | -34.716 | ||
| Beta | 0.4962 | ||
| 3-Year Sharpe Ratio | -0.09 | ||
| 3-Year Sortino Ratio | -0.15 | ||
| Volatility % | 45.07 | ||
| 14-Day RSI | 47.52 | ||
| 14-Day ATR (円) | 7.980827 | ||
| 20-Day SMA (円) | 208.8 | ||
| 12-1 Month Momentum % | 14.81 | ||
| 52-Week Range (円) | 174 - 314 | ||
| Shares Outstanding (Mil) | 49.22 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
MediciNova Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
MediciNova Inc Stock Events
| Event | Date | Price (円) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 135 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 45 days | ||
| General meeting for 2026 | 2026-06-23 13:00 | 209.00 (-1.88%) | ||
| General meeting for 2026 | 2026-06-17 13:00 | 207.00 (+2.99%) | ||
| First quarter earnings results for 2026 | 2026-05-20 | 226.00 (+0.89%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 216.00 (-2.26%) | ||
| Annual report for 2025 | 2026-03-10 | 219.00 (-2.23%) | ||
| Third quarter earnings results for 2025 | 2025-11-12 | 237.00 (+4.87%) | ||
| LD Micro Main Event XIX Investor Conference | 2025-10-20 13:30 | 185.00 (-0.54%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 195.00 (+0.52%) |
Show
Entries
MediciNova Inc Frequently Asked Questions
What is MediciNova Inc(TSE:4875)'s stock price today?
The current price of TSE:4875 is 円209.00. The 52 week high of TSE:4875 is 円314.00 and 52 week low is 円174.00.
When is next earnings date of MediciNova Inc(TSE:4875)?
The next earnings date of MediciNova Inc(TSE:4875) is 2026-08-14 Est..
Does MediciNova Inc(TSE:4875) pay dividends? If so, how much?
MediciNova Inc(TSE:4875) does not pay dividend.
Press Release
Articles on MediciNova Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers